ライフサイエンスコーパス: squamous cell

1 Most cancers were T1 (65%) and squamous cell (45%).

2 show that conditional activation of Notch in squamous cells activates a context-specific gene express

3 We found GSTT2 to protect esophageal squamous cells against DNA damage from genotoxic stress

4 owth factor receptor-dependent head and neck squamous cell cancer (HNSCC) cell lines and a synthetic

5 ce severe acute toxicities for head and neck squamous cell cancer (HNSCC) patients treated with conco

6 egression up to 50% in the treatment of lung squamous cell cancer in mice.

7 ents were significantly higher than those of squamous cell cancer patients.

8 body used for the treatment of head and neck squamous cell cancer, but despite the benefits of adding

9 In head and neck squamous cell cancer, the human epidermal growth factor

10 cohorts: urothelial carcinoma, head and neck squamous-cell cancer (HNSCC), non-small-cell lung cancer

11 These include 2 with squamous cell cancers, 2 with melanoma, 1 with renal cel

12 y), sebaceous gland carcinoma (35 patients), squamous cell carcinoma (26 patients), Merkel cell carci

13 The majority of patients had squamous cell carcinoma (87.8%).

14 usted OR = 0.86; 95% CI: 0.80-0.92), but not squamous cell carcinoma (adjusted OR = 0.99; 95% CI: 0.9

15 Our previous miRNAs array of cervical squamous cell carcinoma (CSCC) clinical specimens identi

16 elanoma skin cancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) is caused by solar ultrav

17 Nonmelanoma skin cancer such as cutaneous squamous cell carcinoma (cSCC) is the most common form o

18 invasion (PNI) and desmoplasia on cutaneous squamous cell carcinoma (CSCC) recurrence and metastasis

19 RNA screen to identify targets for cutaneous squamous cell carcinoma (cSCC) therapy in the ubiquitin/

20 ar composition and architecture of cutaneous squamous cell carcinoma (cSCC), we combined single-cell

21 ansplant recipient with metastatic cutaneous squamous cell carcinoma (CSCC).

22 recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 7

23 Cutaneous squamous cell carcinoma (cuSCC) is the second most commo

24 y to ultraviolet radiation-induced cutaneous squamous cell carcinoma (cuSCC).

25 Equine penile squamous cell carcinoma (EpSCC) is a relatively common c

26 n a detailed immune cell atlas of esophageal squamous cell carcinoma (ESCC) at single-cell resolution

27 hy as a potential risk factor for esophageal squamous cell carcinoma (ESCC) have been inconsistent.

28 r, drug sensitivity biomarkers in esophageal squamous cell carcinoma (ESCC) have not been widely expl

29 Esophageal squamous cell carcinoma (ESCC) is among the most aggress

30 l dependency in SMARCA2-deficient esophageal squamous cell carcinoma (ESCC) models, reciprocal to the

31 nd regulatory mechanism of YAP in esophageal squamous cell carcinoma (ESCC) remains unclear.

32 Detection of patients with esophageal squamous cell carcinoma (ESCC) who do not benefit from s

33 A-31 (miR-31) is overexpressed in esophageal squamous cell carcinoma (ESCC), a deadly disease associa

34 axis occurs at high frequency in esophageal squamous cell carcinoma (ESCC), where it promotes ESCC d

35 the etiology and pathogenesis of esophageal squamous cell carcinoma (ESCC).

36 acterize the oncogenic drivers of esophageal squamous cell carcinoma (ESCC).

37 is linked to an increased risk of esophageal squamous cell carcinoma (ESCC).

38 In a mouse model of hypopharyngeal squamous cell carcinoma (FaDu), APT MRI showed that a re

39 -like protease/differentially expressed in a squamous cell carcinoma (HAT/DESC) cluster of membrane-a

40 d that cortex genes subdivided Head and Neck Squamous Cell Carcinoma (HNSC) tumors and Pheochromocyto

41 h newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinica

42 Head and neck squamous cell carcinoma (HNSCC) arises through exposure

43 Head and neck squamous cell carcinoma (HNSCC) associated with high-ris

44 n of metastatic lymph nodes in head and neck squamous cell carcinoma (HNSCC) cases.

45 an lung cancer cells and human head and neck squamous cell carcinoma (HNSCC) cell lines (UM-SCC-47 an

46 Interrogation of head and neck squamous cell carcinoma (HNSCC) cell lines and patient t

47 Although head and neck squamous cell carcinoma (HNSCC) has in the past been lar

48 Head and neck squamous cell carcinoma (HNSCC) is a common and debilita

49 Head and neck squamous cell carcinoma (HNSCC) is a disease of signific

50 papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) is biologically distinct

51 Head and neck squamous cell carcinoma (HNSCC) is characterized by the

52 Head and neck squamous cell carcinoma (HNSCC) is the sixth most common

53 Tumor hypoxia in head-and-neck squamous cell carcinoma (HNSCC) leads to an immunosuppre

54 Malignant features of head and neck squamous cell carcinoma (HNSCC) may be derived from the

55 Head and neck squamous cell carcinoma (HNSCC) presents a major public

56 Cells from head and neck squamous cell carcinoma (HNSCC) primary tumors had signi

57 val in patients with recurrent head and neck squamous cell carcinoma (HNSCC) than chest x-ray (CXR) p

58 3), a metastatic biomarker for head and neck squamous cell carcinoma (HNSCC), along with two accompan

59 In head and neck squamous cell carcinoma (HNSCC), cell migration facilita

60 roved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the managem

61 t the two most common sites of head and neck squamous cell carcinoma (HNSCC), the lateral border of t

62 containing 4 (ZSCAN4) in human head and neck squamous cell carcinoma (HNSCC).

63 s with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC).

64 resistance, and recurrence in head and neck squamous cell carcinoma (HNSCC).

65 and are known collectively as head and neck squamous cell carcinoma (HNSCC).

66 (chemo)radiotherapy (CRT) for head and neck squamous cell carcinoma (HNSCC).

67 t commonly altered oncogene in head and neck squamous cell carcinoma (HNSCC).

68 ab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC).

69 promises for the treatment of head and neck squamous cell carcinoma (HNSCC).

70 ipheral blood in patients with head and neck squamous cell carcinoma (HNSCC).

71 benefit in most patients with head and neck squamous cell carcinoma (HNSCC).

72 cological decision support for Head and Neck Squamous Cell Carcinoma (HNSCC).

73 nt escalation in patients with head and neck squamous cell carcinoma (HNSCC).

74 nhibits the activity of CBI in head and neck squamous cell carcinoma (HNSCC).

75 lified and overexpressed in head and neck of squamous cell carcinoma (HNSCC).

76 as a first-line treatment for head and neck squamous cell carcinoma (HNSCC).

77 of immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC).

78 s with locoregionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according t

79 o human papillomavirus-related oropharyngeal squamous cell carcinoma (HPV + OPSCC).

80 Lung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC)

81 Mechanisms of lung squamous cell carcinoma (LSCC) development are poorly un

82 Laryngeal squamous cell carcinoma (LSCC) responds to 17beta-estrad

83 lidated in a secondary unrelated set of lung squamous cell carcinoma (LUSC) and was shown to be drive

84 eal adenocarcinoma (EA; n = 855), esophageal squamous cell carcinoma (n = 267), and gastric cancer (c

85 the combined outcome laryngeal or pharyngeal squamous cell carcinoma (n = 39) were decreased after an

86 Invasive squamous cell carcinoma (n = 51, 41%) was the most commo

87 tumor proportion score [TPS] >= 50%) and non-squamous cell carcinoma (non-SCC), the Expert Panel reco

88 pression data from patients with oral cavity squamous cell carcinoma (OCSCC) in order to map metabolo

89 The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rapidly increas

90 Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing

91 ortant determinant of oral and oropharyngeal squamous cell carcinoma (OPSCC) outcomes, yet most of th

92 trace elemental composition of oropharyngeal squamous cell carcinoma (OPSCC), we performed elemental

93 apillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).

94 New therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed.

95 voke cancer pain.SIGNIFICANCE STATEMENT Oral squamous cell carcinoma (OSCC) is one of the most painfu

96 Oral squamous cell carcinoma (OSCC) is one of the most painfu

97 Oral squamous cell carcinoma (OSCC) is the most common head a

98 Oral squamous cell carcinoma (OSCC) is the most common malign

99 Oral squamous cell carcinoma (OSCC) is the most common type o

100 ess this gap, we used a murine model of oral squamous cell carcinoma (OSCC) of the tongue to investig

101 Patients with oral squamous cell carcinoma (OSCC) present significant alter

102 Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is the eighth-most commo

103 esis mirrors the heterogeneity of human oral squamous cell carcinoma (OSCC), we have performed genomi

104 egional lymph node metastasis (RLNM) in oral squamous cell carcinoma (OSCC).

105 results and revolutionizes treatment of oral squamous cell carcinoma (OSCC).

106 by genetic alterations in patients with oral squamous cell carcinoma (OSCC).

107 apillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OSCC).

108 Penile squamous cell carcinoma (PSCC) accounts for over 95% of

109 The incidence of penile squamous cell carcinoma (PSCC) has increased in develope

110 resectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of PD-L1 expression)

111 f transcription factors, is overexpressed in squamous cell carcinoma (SCC) and associated with poor p

112 -value thresholds were chosen from published squamous cell carcinoma (SCC) and basal cell carcinoma (

113 Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are both derived from epid

114 is (AK), Intraepidermal Carcinoma (IEC), and Squamous Cell Carcinoma (SCC) are generally considered t

115 Murine squamous cell carcinoma (SCC) can be initiated by hair f

116 Epidermal squamous cell carcinoma (SCC) is a common and highly inv

117 Squamous cell carcinoma (SCC) is a global public health

118 Cutaneous squamous cell carcinoma (SCC) is one of the most common

119 ctrum of diseases from dysplasia to invasive squamous cell carcinoma (SCC) of the conjunctiva.

120 prone actinic keratoses (AKs) and aggressive squamous cell carcinoma (SCC) subtypes.

121 problem, we designed a skin cancer model for squamous cell carcinoma (SCC) that can be effectively ch

122 tematic review describing the burden of anal squamous cell carcinoma (SCC), and its surrogates, in SO

123 f medical comorbidities, lower proportion of squamous cell carcinoma (SCC), and more positive lymph n

124 cal benefits in adenocarcinoma (ADC) but not squamous cell carcinoma (SCC), even though the stroma is

125 agement for head and neck cancers, including squamous cell carcinoma (SCC), involves surgical resecti

126 romosome end fusions that also occur in skin Squamous Cell Carcinoma (SCC)-associated CAFs, in which

127 tures of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

128 l cell carcinoma (BCC) or invasive cutaneous squamous cell carcinoma (SCC).

129 in adenocarcinoma (ADC, 72.5%) compared with squamous cell carcinoma (SQCC, 54.4%).

130 possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma.

131 gically confirmed locally advanced cutaneous squamous cell carcinoma and an Eastern Cooperative Oncol

132 is contemporary cohort include prior CLL for squamous cell carcinoma and basal cell carcinoma and red

133 er lead to specific immunophenotypes in lung squamous cell carcinoma and could potentially serve as b

134 SVC112 reduces tumor growth in head and neck squamous cell carcinoma and increases the effects of rad

135 single-agent treatment in both head and neck squamous cell carcinoma and non-small cell lung cancer.

136 x surgery may decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal

137 are transcriptionally regulated by SPIN1 in squamous cell carcinoma and suggest that SPIN1 may have

138 nsive loss of heterozygosity, including lung squamous cell carcinoma and triple-negative breast cance

139 ical (PEC) immunosensor by immobilizing anti-squamous cell carcinoma antigen (anti-SCCA).

140 ell lung cancer (NSCLC) cells, we identified squamous cell carcinoma antigen recognized by T-cells 3

141 e-matched tumors from patients with basal or squamous cell carcinoma before and after anti-PD-1 thera

142 In addition, knockout of ZDHHC19 in lung squamous cell carcinoma cells significantly blocks STAT3

143 uman papillomavirus-associated oropharyngeal squamous cell carcinoma could maintain historical rates

144 Female patients had higher incidence of squamous cell carcinoma despite lower prevalence of beha

145 from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion

146 ultiple myeloma, oral cancer, and esophageal squamous cell carcinoma did not survive correction for m

147 is approach to a sample of 525 head and neck squamous cell carcinoma exomes, producing a rank-ordered

148 in patients with locally advanced cutaneous squamous cell carcinoma for whom there was no widely acc

149 te staging of viral-associated oropharyngeal squamous cell carcinoma from tobacco and alcohol use-ass

150 d alpha-ketoglutarate production antagonizes squamous cell carcinoma growth.

151 papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated

152 Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with convent

153 Squamous cell carcinoma in situ (SCCIS) is a prevalent p

154 successfully established a PDX model of lung squamous cell carcinoma in which the grafts recapitulate

155 WLHIV) have disproportionately high rates of squamous cell carcinoma of the anus compared with the ge

156 f Gynecology and Obstetrics (FIGO) stage IB3 squamous cell carcinoma of the cervix.

157 atients with biopsy-proven adenocarcinoma or squamous cell carcinoma of the esophagus with an initial

158 al cell carcinoma (RCC), endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN), me

159 To identify genetic variants for risk of squamous cell carcinoma of the head and neck (SCCHN), we

160 ased chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

161 endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-smal

162 the management of the neck in patients with squamous cell carcinoma of the oral cavity and oropharyn

163 nts with platinum-resistant or early-failure squamous cell carcinoma of the oral cavity were eligible

164 Remarkably high risks for second in situ squamous cell carcinoma of the skin were found after Kap

165 Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 r

166 In particular, the risk of squamous cell carcinoma of the skin-which has been assoc

167 ere identified for each invasive and in situ squamous cell carcinoma of the skin.

168 erapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival p

169 ndices of UVB-induced DNA damage and delayed squamous cell carcinoma onset induced by chronic UVB.

170 Lung adenocarcinoma and lung squamous cell carcinoma patients had the lowest survival

171 al rates of lung, cervical and head and neck squamous cell carcinoma patients.

172 dence rates, prognosis of invasive cutaneous squamous cell carcinoma remains poor, mainly due to lack

173 es demonstrate that reduced FEV(1) increases squamous cell carcinoma risk (odds ratio (OR) = 1.51, 95

174 Here, we analyzed a dataset of lung squamous cell carcinoma samples from The Cancer Genome A

175 mor xenograft/allograft (human head and neck squamous cell carcinoma SAS/mouse breast carcinoma 4T1)

176 s with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation o

177 Vmax and EUS for nodal disease was higher in squamous cell carcinoma than adenocarcinoma.

178 ter chemopreventive efficacy for UVB-induced squamous cell carcinoma than melanoma mouse models.

179 Patients with head-and-neck squamous cell carcinoma that progressed during or after

180 rend to higher overall complication rates in squamous cell carcinoma versus adenocarcinoma (65% vs 51

181 d adenocarcinoma (83%); however, the rate of squamous cell carcinoma was significantly higher in fema

182 The risk estimates of laryngeal squamous cell carcinoma were particularly decreased >10

183 Patients with head and neck squamous cell carcinoma who underwent surgical resection

184 35), and a significant difference in ARDS in squamous cell carcinoma with 14% versus 2% in adenocarci

185 prostate, pancreas, lung adenocarcinoma, and squamous cell carcinoma) for the frequency of codon muta

186 with cryotherapy: 5 conjunctival melanoma, 4 squamous cell carcinoma, 1 sebaceous carcinoma, and 1 at

187 ses (including 11,273 adenocarcinomas, 7,426 squamous cell carcinoma, and 2,664 small-cell carcinoma

188 g this pipeline to lung adenocarcinoma, lung squamous cell carcinoma, and glioblastoma, genes highly

189 ith increasing risks of lung adenocarcinoma, squamous cell carcinoma, and small cell carcinoma.

190 In SKH1-E mice prone to squamous cell carcinoma, ASA reduced plasma and skin pro

191 in certain types of cancer cells, including squamous cell carcinoma, brain tumor, and osteosarcoma,

192 ignant lesions (PMLs) are precursors of lung squamous cell carcinoma, but have variable outcome, and

193 In lung adenocarcinoma, but not lung squamous cell carcinoma, geometrical irregularity and co

194 onary infection, as well as autoimmunity and squamous cell carcinoma, in addition to even more broad

195 esponsive skin cancers, invasive and in situ squamous cell carcinoma, Kaposi sarcoma, and Merkel cell

196 n and risk of oesophageal adenocarcinoma and squamous cell carcinoma, liver and endometrial cancer we

197 space invasion, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of t

198 In human actinic keratosis, a precursor of squamous cell carcinoma, p16(INK4a)-expressing cells are

199 For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy

200 Subjects with basal or squamous cell carcinoma, scheduled for Mohs surgery, wer

201 ded patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-year

202 We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role i

203 phological stages of the development of lung squamous cell carcinoma, which includes 122 well-annotat

204 umor microenvironment (TME) of head and neck squamous cell carcinoma.

205 lls (EpdSCs), which are a cell of origin for squamous cell carcinoma.

206 ectrum of oral epithelial dysplasia and oral squamous cell carcinoma.

207 time after surgery was found for pharyngeal squamous cell carcinoma.

208 ux surgery prevents laryngeal and pharyngeal squamous cell carcinoma.

209 ncrease the risk of laryngeal and pharyngeal squamous cell carcinoma.

210 in patients with locally advanced cutaneous squamous cell carcinoma.

211 tivity in patients with metastatic cutaneous squamous cell carcinoma.

212 associated with esophageal adenocarcinoma or squamous cell carcinoma.

213 have sex with men (MSM) are at risk of anal squamous cell carcinoma.

214 cerous lesion that can progress to cutaneous squamous cell carcinoma.

215 and also the leading cause of mortality - is squamous cell carcinoma.

216 rstanding of carcinogenesis in head and neck squamous cell carcinoma.

217 or for nonmelanoma skin cancer, particularly squamous cell carcinoma.

218 cells and evident in patients with basal or squamous cell carcinoma.

219 ival PL with and without progression to oral squamous cell carcinoma.

220 ant anti-cancer therapy in human oral cavity squamous cell carcinoma.

221 uman papillomavirus-associated oropharyngeal squamous cell carcinoma.

222 ll carcinoma and possibly also of pharyngeal squamous cell carcinoma.

223 Biopsy revealed poorly differentiated, squamous cell carcinoma.

224 d efficacy in the treatment of head and neck squamous cell carcinoma.

225 1 is highly expressed in CSCs of oral cavity squamous cell carcinoma.

226 e therapy for the treatment of head-and-neck squamous cell carcinoma.

227 , contribute to the development of cutaneous squamous cell carcinoma.

228 s with recurrent or metastatic head-and-neck squamous cell carcinoma.

229 ll cell carcinoma, urothelial carcinoma, and squamous cell carcinoma.

230 and metastasis of mouse and human cutaneous squamous cell carcinoma.

231 noma from tobacco and alcohol use-associated squamous cell carcinoma.

232 d highly aggressive form of undifferentiated squamous cell carcinoma.

233 rspective in a mouse model of salivary gland squamous cell carcinoma.

234 on appearance and risk factors in predicting squamous cell carcinoma.

235 s on the incidence of cases of invasive anal squamous-cell carcinoma (IASCC) in persons with HIV-1, w

236 ffer from other solid tumors like esophageal squamous-cell carcinoma or glioma.

237 uman papillomavirus-associated oropharyngeal squamous-cell carcinoma stabilized, and quality of life

238 s on the incidence of cases of invasive-anal-squamous-cell-carcinoma (IASCC) in HIV-1-infected subjec

239 papillomaviruses (beta-HPVs) cause cutaneous squamous cell carcinomas (cSCCs) in a subset of immunoco

240 as co-factor in the development of cutaneous squamous cell carcinomas (cSCCs), particularly in immuno

241 une microenvironment (TIME) of head and neck squamous cell carcinomas (HNSCC) and other solid maligna

242 n, with disparate incidence of head and neck squamous cell carcinomas (HNSCC), including oral cavity

243 me high FGF19 amplification in head and neck squamous cell carcinomas (HNSCC), which is associated wi

244 treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure

245 mal 1 (FXR1) is upregulated in head and neck squamous cell carcinomas (HNSCCs) and expressed as at le

246 nging therapeutic landscape of head and neck squamous cell carcinomas (HNSCCs) that can arise in the

247 anisms remain undefined in the head and neck squamous cell carcinomas (HNSCCs).

248 The incidences of squamous cell carcinomas (incidence rate ratio = 9.8; 95

249 tome data of lung adenocarcinomas (LUAD) and squamous cell carcinomas (LUSC) from The Cancer Genome A

250 r human papillomavirus- driven oropharyngeal squamous cell carcinomas (OpSCC) represent distinct clin

251 HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCC) we noticed that, while

252 y but insufficient cause of a subset of oral squamous cell carcinomas (OSCCs) that is increasing mark

253 hageal cancers and were more associated with squamous cell carcinomas (P = 0.04).

254 is development and a key oncogenic driver in squamous cell carcinomas (SCC).

255 Squamous cell carcinomas (SCCs) account for the majority

256 Skin squamous cell carcinomas (SCCs) are a major cause of dea

257 Squamous cell carcinomas (SCCs) arising from aerodigesti

258 We report that CAFs from skin squamous cell carcinomas (SCCs) display chromosomal alte

259 Advanced and undifferentiated skin squamous cell carcinomas (SCCs) exhibit aggressive growt

260 Examination of human papillomas and squamous cell carcinomas (SCCs) revealed that TC-PTP exp

261 Two histologic subtypes of squamous cell carcinomas (SCCs) were identified-SCCs wit

262 ut of 147 primary cervical cancers, 113 were squamous cell carcinomas (SCCs), and 34 were adenocarcin

263 Oral cancers, primarily squamous cell carcinomas (SCCs), progress either slowly

264 -3.86), for basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), respectively.

265 melanomas, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs).

266 ing head and neck, cervical and oesophageal, squamous cell carcinomas display loss of ZNF185 expressi

267 andscape in the development of head and neck squamous cell carcinomas HNSCC from potentially premalig

268 coexpressing IL23 in the stroma of cervical squamous cell carcinomas in situ.

269 and potentiates the progression of invasive squamous cell carcinomas in vivo.

270 cell carcinomas form 'buds', while invasive squamous cell carcinomas initiate as 'folds'.

271 the HER2 signaling axis to drive aggressive squamous cell carcinomas of the head and neck (HNSCC) an

272 Squamous cell carcinomas of the head and neck (HNSCC) ar

273 trated clinical efficacy in the treatment of squamous cell carcinomas of the head and neck.

274 of ocular surface or ocular adnexal invasive squamous cell carcinomas were identified in pathology ca

275 In multivariable models, risk factors for squamous cell carcinomas were increased age (P < 0.0001)

276 BCCs usually maintain HH pathway activation, squamous cell carcinomas with Ras/MAPK pathway activatio

277 Keratinocyte carcinomas, including basal and squamous cell carcinomas, are the most common human canc

278 fferentiation and is frequently disrupted in squamous cell carcinomas, in which Notch is tumor suppre

279 se phenformin for the treatment of cutaneous squamous cell carcinomas.

280 past history of numerous cutaneous basal and squamous cell carcinomas.

281 TET1 is overexpressed in adenocarcinoma and squamous cell carcinomas.

282 iple human cancers, including in 39% of lung squamous cell carcinomas.

283 Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16(INK4

284 r female and male genital and anal) and skin squamous cell CIS; additionally RRs were assessed betwee

285 rbachol ex vivo and that mucosa demonstrated squamous cell differentiation.

286 sly described mouse "hillock" cells and with squamous cells expressing SCEL and SPRR1A/B.Conclusions:

287 GSTT2 protected Het-1A esophageal squamous cells from cum-OOH-induced DNA damage.

288 on in submerged airway RPMI 2650 or NCI-H520 squamous cells increased intracellular calcium levels an

289 and expression proteomics in a cohort of 108 squamous cell lung cancer (SCC) patients.

290 mechanisms for palbociclib were explored in squamous cell lung cancer (SqCLC), the second most commo

291 hree or more epitopes that were distinct for squamous cell lung cancer and lung adenocarcinoma, respe

292 and DNA-damage response pathways converge in squamous cells on common genes that promote differentiat

293 locoregional residual disease after nCRT for squamous cell- or adenocarcinoma.

294 rus-associated exacerbations, in contrast to squamous cell pathways associated with nonviral exacerba

295 Notch signaling regulates squamous cell proliferation and differentiation and is f

296 It is called squamous cell prostate carcinoma.

297 rdial germ cell positioning, and cuboidal-to-squamous cell shape transitions in the extraembryonic se

298 to the well-established two-step protocol of squamous cell skin carcinoma, in which tumorigenesis is

299 eads to extrusion of veil cell daughters and squamous cells, suggesting veil cell fate is regulated b

300 Squamous cells with nuclear F-actin staining were associ